REC-3964 is Recursion’s first new chemical entity developed using the RecursionOS. REC-3964 represents a novel, non-antibiotic approach with a unique mechanism of action that binds and blocks ...
Recursion Pharmaceuticals leverages AI and machine learning to revolutionize drug discovery, reducing costs and accelerating development, positioning itself as a leader in tech-driven biopharma. The ...
Recursion, Roche, and its Genentech subsidiary have unveiled the latest product of their nearly four-year artificial intelligence (AI) drug discovery collaboration, a whole-genome map of specialized ...
Recursion's AI-enabled drug discovery platform continues to evolve, but this is yet to translate into meaningful clinical success. The recent cull of programs has further undermined investor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results